- Only company in the world with patent for the oral or ingestible delivery of all non-psychoactive cannabinoids
- Uplisted to OTCQX® Best Market
- Licensing model generates profit margins in excess of 90 percent
A new report by the National Academies of Sciences, Engineering and Medicine is the most comprehensive analysis of existing research on e-cigarettes, according to the New York Times (http://cnw.fm/Eay21). While warning against the risk of nicotine addiction posed by vaping, the report claimed “that the devices are safer than traditional smoking products and may help smokers quit, citing conclusive proof that switching can reduce smokers’ exposure to deadly tar, dangerous chemicals and other carcinogens.” Although nicotine is most often cited in indictments against smoking, it is not a carcinogen and appears to have little effect on cardiovascular health. Indeed, its use has been credited with health benefits (http://cnw.fm/Bay7u), with its bad rap being attributed to its method of delivery, such as inhaling tobacco smoke. This report highlights the importance of drug delivery methodologies like those developed by Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP). The company, recently uplisted to the OTCQX® Best Market, has developed technology that allows nicotine to be absorbed without smoking.
Lexaria’s DehydraTECH™ oral digestion technology is a ‘back office’ process that allows non-psychoactive cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and nicotine to be absorbed at much higher rates. The company has been working with the National Research Council of Canada (“NRC”), an agency of the Canadian federal government, to explore…
More from CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.CannabisNewsWire.com